Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors Post published:August 25, 2022 Post category:Press Release
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Post published:August 25, 2022 Post category:Press Release
FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL Post published:August 25, 2022 Post category:Press Release
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects Post published:August 25, 2022 Post category:Press Release
Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment Post published:August 24, 2022 Post category:Press Release
Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position Post published:August 24, 2022 Post category:Press Release
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates Post published:August 23, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Private Placement Post published:August 20, 2022 Post category:Press Release
HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments and the Issuance of Shares for Debt Post published:August 19, 2022 Post category:Press Release
Bright Minds Biosciences Comments on Recent Trading Activity Post published:August 18, 2022 Post category:Press Release